1 Market Overview
1.1 Non-alcoholic Steatohepatitis Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Non-alcoholic Steatohepatitis Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Solid
1.2.3 Liquid
1.3 Market Analysis by Application
1.3.1 Overview: Global Non-alcoholic Steatohepatitis Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Oral
1.3.3 Parenteral
1.4 Global Non-alcoholic Steatohepatitis Market Size & Forecast
1.4.1 Global Non-alcoholic Steatohepatitis Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Non-alcoholic Steatohepatitis Sales in Volume (2017-2028)
1.4.3 Global Non-alcoholic Steatohepatitis Price (2017-2028)
1.5 Global Non-alcoholic Steatohepatitis Production Capacity Analysis
1.5.1 Global Non-alcoholic Steatohepatitis Total Production Capacity (2017-2028)
1.5.2 Global Non-alcoholic Steatohepatitis Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Non-alcoholic Steatohepatitis Market Drivers
1.6.2 Non-alcoholic Steatohepatitis Market Restraints
1.6.3 Non-alcoholic Steatohepatitis Trends Analysis
2 Manufacturers Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca Non-alcoholic Steatohepatitis Product and Services
2.1.4 AstraZeneca Non-alcoholic Steatohepatitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Arena Pharmaceuticals
2.2.1 Arena Pharmaceuticals Details
2.2.2 Arena Pharmaceuticals Major Business
2.2.3 Arena Pharmaceuticals Non-alcoholic Steatohepatitis Product and Services
2.2.4 Arena Pharmaceuticals Non-alcoholic Steatohepatitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 GSK
2.3.1 GSK Details
2.3.2 GSK Major Business
2.3.3 GSK Non-alcoholic Steatohepatitis Product and Services
2.3.4 GSK Non-alcoholic Steatohepatitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Novo Nordisk
2.4.1 Novo Nordisk Details
2.4.2 Novo Nordisk Major Business
2.4.3 Novo Nordisk Non-alcoholic Steatohepatitis Product and Services
2.4.4 Novo Nordisk Non-alcoholic Steatohepatitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Roche
2.5.1 Roche Details
2.5.2 Roche Major Business
2.5.3 Roche Non-alcoholic Steatohepatitis Product and Services
2.5.4 Roche Non-alcoholic Steatohepatitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Vivus
2.6.1 Vivus Details
2.6.2 Vivus Major Business
2.6.3 Vivus Non-alcoholic Steatohepatitis Product and Services
2.6.4 Vivus Non-alcoholic Steatohepatitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Arisaph Pharmaceuticals
2.7.1 Arisaph Pharmaceuticals Details
2.7.2 Arisaph Pharmaceuticals Major Business
2.7.3 Arisaph Pharmaceuticals Non-alcoholic Steatohepatitis Product and Services
2.7.4 Arisaph Pharmaceuticals Non-alcoholic Steatohepatitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Cempra Pharmaceuticals
2.8.1 Cempra Pharmaceuticals Details
2.8.2 Cempra Pharmaceuticals Major Business
2.8.3 Cempra Pharmaceuticals Non-alcoholic Steatohepatitis Product and Services
2.8.4 Cempra Pharmaceuticals Non-alcoholic Steatohepatitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Galectin Therapeutics
2.9.1 Galectin Therapeutics Details
2.9.2 Galectin Therapeutics Major Business
2.9.3 Galectin Therapeutics Non-alcoholic Steatohepatitis Product and Services
2.9.4 Galectin Therapeutics Non-alcoholic Steatohepatitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Galmed Pharmaceuticals
2.10.1 Galmed Pharmaceuticals Details
2.10.2 Galmed Pharmaceuticals Major Business
2.10.3 Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Product and Services
2.10.4 Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Genfit
2.11.1 Genfit Details
2.11.2 Genfit Major Business
2.11.3 Genfit Non-alcoholic Steatohepatitis Product and Services
2.11.4 Genfit Non-alcoholic Steatohepatitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Gilead
2.12.1 Gilead Details
2.12.2 Gilead Major Business
2.12.3 Gilead Non-alcoholic Steatohepatitis Product and Services
2.12.4 Gilead Non-alcoholic Steatohepatitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 Immuron
2.13.1 Immuron Details
2.13.2 Immuron Major Business
2.13.3 Immuron Non-alcoholic Steatohepatitis Product and Services
2.13.4 Immuron Non-alcoholic Steatohepatitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14 Interceptpharma
2.14.1 Interceptpharma Details
2.14.2 Interceptpharma Major Business
2.14.3 Interceptpharma Non-alcoholic Steatohepatitis Product and Services
2.14.4 Interceptpharma Non-alcoholic Steatohepatitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15 Raptor Pharmaceutical
2.15.1 Raptor Pharmaceutical Details
2.15.2 Raptor Pharmaceutical Major Business
2.15.3 Raptor Pharmaceutical Non-alcoholic Steatohepatitis Product and Services
2.15.4 Raptor Pharmaceutical Non-alcoholic Steatohepatitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16 Takeda
2.16.1 Takeda Details
2.16.2 Takeda Major Business
2.16.3 Takeda Non-alcoholic Steatohepatitis Product and Services
2.16.4 Takeda Non-alcoholic Steatohepatitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17 Tobira Therapeutics
2.17.1 Tobira Therapeutics Details
2.17.2 Tobira Therapeutics Major Business
2.17.3 Tobira Therapeutics Non-alcoholic Steatohepatitis Product and Services
2.17.4 Tobira Therapeutics Non-alcoholic Steatohepatitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18 Verva
2.18.1 Verva Details
2.18.2 Verva Major Business
2.18.3 Verva Non-alcoholic Steatohepatitis Product and Services
2.18.4 Verva Non-alcoholic Steatohepatitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.19 Viking Therapeutics
2.19.1 Viking Therapeutics Details
2.19.2 Viking Therapeutics Major Business
2.19.3 Viking Therapeutics Non-alcoholic Steatohepatitis Product and Services
2.19.4 Viking Therapeutics Non-alcoholic Steatohepatitis Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Non-alcoholic Steatohepatitis Breakdown Data by Manufacturer
3.1 Global Non-alcoholic Steatohepatitis Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Non-alcoholic Steatohepatitis Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Non-alcoholic Steatohepatitis
3.4 Market Concentration Rate
3.4.1 Top 3 Non-alcoholic Steatohepatitis Manufacturer Market Share in 2021
3.4.2 Top 6 Non-alcoholic Steatohepatitis Manufacturer Market Share in 2021
3.5 Global Non-alcoholic Steatohepatitis Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Non-alcoholic Steatohepatitis Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Non-alcoholic Steatohepatitis Market Size by Region
4.1.1 Global Non-alcoholic Steatohepatitis Sales in Volume by Region (2017-2028)
4.1.2 Global Non-alcoholic Steatohepatitis Revenue by Region (2017-2028)
4.2 North America Non-alcoholic Steatohepatitis Revenue (2017-2028)
4.3 Europe Non-alcoholic Steatohepatitis Revenue (2017-2028)
4.4 Asia-Pacific Non-alcoholic Steatohepatitis Revenue (2017-2028)
4.5 South America Non-alcoholic Steatohepatitis Revenue (2017-2028)
4.6 Middle East and Africa Non-alcoholic Steatohepatitis Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Non-alcoholic Steatohepatitis Sales in Volume by Type (2017-2028)
5.2 Global Non-alcoholic Steatohepatitis Revenue by Type (2017-2028)
5.3 Global Non-alcoholic Steatohepatitis Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Non-alcoholic Steatohepatitis Sales in Volume by Application (2017-2028)
6.2 Global Non-alcoholic Steatohepatitis Revenue by Application (2017-2028)
6.3 Global Non-alcoholic Steatohepatitis Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Non-alcoholic Steatohepatitis Sales by Type (2017-2028)
7.2 North America Non-alcoholic Steatohepatitis Sales by Application (2017-2028)
7.3 North America Non-alcoholic Steatohepatitis Market Size by Country
7.3.1 North America Non-alcoholic Steatohepatitis Sales in Volume by Country (2017-2028)
7.3.2 North America Non-alcoholic Steatohepatitis Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Non-alcoholic Steatohepatitis Sales by Type (2017-2028)
8.2 Europe Non-alcoholic Steatohepatitis Sales by Application (2017-2028)
8.3 Europe Non-alcoholic Steatohepatitis Market Size by Country
8.3.1 Europe Non-alcoholic Steatohepatitis Sales in Volume by Country (2017-2028)
8.3.2 Europe Non-alcoholic Steatohepatitis Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Non-alcoholic Steatohepatitis Sales by Type (2017-2028)
9.2 Asia-Pacific Non-alcoholic Steatohepatitis Sales by Application (2017-2028)
9.3 Asia-Pacific Non-alcoholic Steatohepatitis Market Size by Region
9.3.1 Asia-Pacific Non-alcoholic Steatohepatitis Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Non-alcoholic Steatohepatitis Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Non-alcoholic Steatohepatitis Sales by Type (2017-2028)
10.2 South America Non-alcoholic Steatohepatitis Sales by Application (2017-2028)
10.3 South America Non-alcoholic Steatohepatitis Market Size by Country
10.3.1 South America Non-alcoholic Steatohepatitis Sales in Volume by Country (2017-2028)
10.3.2 South America Non-alcoholic Steatohepatitis Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Non-alcoholic Steatohepatitis Sales by Type (2017-2028)
11.2 Middle East & Africa Non-alcoholic Steatohepatitis Sales by Application (2017-2028)
11.3 Middle East & Africa Non-alcoholic Steatohepatitis Market Size by Country
11.3.1 Middle East & Africa Non-alcoholic Steatohepatitis Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Non-alcoholic Steatohepatitis Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Non-alcoholic Steatohepatitis and Key Manufacturers
12.2 Manufacturing Costs Percentage of Non-alcoholic Steatohepatitis
12.3 Non-alcoholic Steatohepatitis Production Process
12.4 Non-alcoholic Steatohepatitis Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Non-alcoholic Steatohepatitis Typical Distributors
13.3 Non-alcoholic Steatohepatitis Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
世界の非アルコール性脂肪性肝炎市場2022年：市場規模予測（～2028年） |
| 【英語タイトル】Global Non-alcoholic Steatohepatitis Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028 | |
 | ・商品コード：GIR22DC3562 ・発行会社（調査会社）：GlobalInfoResearch ・発行日：2023年1月 ・ページ数：115 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（注文後2-3日） ・調査対象地域：グローバル ・産業分野：医療機器 |
| Single User（1名様閲覧用） | USD3,480 ⇒換算￥528,960 | 見積依頼/購入/質問フォーム |
| Multi User（20名様閲覧用） | USD5,220 ⇒換算￥793,440 | 見積依頼/購入/質問フォーム |
| Corporate User（同一法人内共有可） | USD6,960 ⇒換算￥1,057,920 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| 非アルコール性脂肪性肝炎市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 GlobalInfoResearchの最新の調査によると、世界の非アルコール性脂肪性肝炎の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 非アルコール性脂肪性肝炎市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメントは次をカバーします。 ・固体状、液体状 用途別セグメントは次のように区分されます。 ・経口、非経口 世界の非アルコール性脂肪性肝炎市場の主要な市場プレーヤーは以下のとおりです。 ・AstraZeneca、Arena Pharmaceuticals、GSK、Novo Nordisk、Roche、Vivus、Arisaph Pharmaceuticals、Cempra Pharmaceuticals、Galectin Therapeutics、Galmed Pharmaceuticals、Genfit、Gilead、Immuron、Interceptpharma、Raptor Pharmaceutical、Takeda、Tobira Therapeutics、Verva、Viking Therapeutics 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、非アルコール性脂肪性肝炎製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要な非アルコール性脂肪性肝炎メーカーの企業概要、2019年～2022年までの非アルコール性脂肪性肝炎の価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要な非アルコール性脂肪性肝炎メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2017年～2028年までの地域別非アルコール性脂肪性肝炎の販売量、売上、成長性を示しています。 ・第5、6章では、2017年～2028年までの非アルコール性脂肪性肝炎の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での非アルコール性脂肪性肝炎市場予測を収録しています。 ・第12章では、主要な原材料、主要なサプライヤー、および非アルコール性脂肪性肝炎の産業チェーンを掲載しています。 ・第13、14、15章では、非アルコール性脂肪性肝炎の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 - 非アルコール性脂肪性肝炎の概要 - 種類別分析（2017年vs2021年vs2028年）：固体状、液体状 - 用途別分析（2017年vs2021年vs2028年）：経口、非経口 - 世界の非アルコール性脂肪性肝炎市場規模・予測 - 世界の非アルコール性脂肪性肝炎生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - AstraZeneca、Arena Pharmaceuticals、GSK、Novo Nordisk、Roche、Vivus、Arisaph Pharmaceuticals、Cempra Pharmaceuticals、Galectin Therapeutics、Galmed Pharmaceuticals、Genfit、Gilead、Immuron、Interceptpharma、Raptor Pharmaceutical、Takeda、Tobira Therapeutics、Verva、Viking Therapeutics ・メーカー別市場シェア・市場集中度 ・地域別市場分析2017年-2028年 ・種類別分析2017年-2028年：固体状、液体状 ・用途別分析2017年-2028年：経口、非経口 ・非アルコール性脂肪性肝炎の北米市場 - 種類別市場規模2017年-2028年 - 用途別市場規模2017年-2028年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・非アルコール性脂肪性肝炎のヨーロッパ市場 - 種類別市場規模2017年-2028年 - 用途別市場規模2017年-2028年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・非アルコール性脂肪性肝炎のアジア市場 - 種類別市場規模2017年-2028年 - 用途別市場規模2017年-2028年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・非アルコール性脂肪性肝炎の南米市場 - 種類別市場規模2017年-2028年 - 用途別市場規模2017年-2028年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・非アルコール性脂肪性肝炎の中東・アフリカ市場 - 種類別市場規模2017年-2028年 - 用途別市場規模2017年-2028年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Non-alcoholic Steatohepatitis market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Non-alcoholic Steatohepatitis market size is estimated to be worth US$ 3277.4 million in 2021 and is forecast to a readjusted size of USD 11540 million by 2028 with a CAGR of 19.7% during review period. Oral accounting for % of the Non-alcoholic Steatohepatitis global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Solid segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Non-alcoholic Steatohepatitis include AstraZeneca, Arena Pharmaceuticals, GSK, Novo Nordisk, and Roche, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Non-alcoholic Steatohepatitis market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Solid
Liquid
Market segment by Application can be divided into
Oral
Parenteral
The key market players for global Non-alcoholic Steatohepatitis market are listed below:
AstraZeneca
Arena Pharmaceuticals
GSK
Novo Nordisk
Roche
Vivus
Arisaph Pharmaceuticals
Cempra Pharmaceuticals
Galectin Therapeutics
Galmed Pharmaceuticals
Genfit
Gilead
Immuron
Interceptpharma
Raptor Pharmaceutical
Takeda
Tobira Therapeutics
Verva
Viking Therapeutics
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Non-alcoholic Steatohepatitis product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Non-alcoholic Steatohepatitis, with price, sales, revenue and global market share of Non-alcoholic Steatohepatitis from 2019 to 2022.
Chapter 3, the Non-alcoholic Steatohepatitis competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Non-alcoholic Steatohepatitis breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Non-alcoholic Steatohepatitis market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Non-alcoholic Steatohepatitis.
Chapter 13, 14, and 15, to describe Non-alcoholic Steatohepatitis sales channel, distributors, customers, research findings and conclusion, appendix and data source.
❖ レポートの目次 ❖
| ★調査レポート[世界の非アルコール性脂肪性肝炎市場2022年：市場規模予測（～2028年）] (コード：GIR22DC3562)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界の非アルコール性脂肪性肝炎市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせ |
